Carolina Espina

Carolina Espina

Auto-generated profile, based on publicly available information

Carolina Espina

Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Annals of Epidemiology
Verified
Journal Article
Open access
CECarolina Espina
Carolina Espina
FMFiona McKenzie
Fiona McKenzie
IDIsabel Dos-Santos-Silva
Isabel Dos-Santos-Silva
Africa has low breast cancer incidence rates but high mortality rates from this disease due to poor survival. Delays in presentation and diagnosis are major determinants of breast cancer survival, but these have not been comprehensively investigated in Africa. MEDLINE, Embase, and Global Health were searched to identify studies reporting on delays in presentation and/or diagnosis of breast cancer published between January 1, 2000 and May 31, 2016. Data were synthesized in narrative, tabular, and graphical forms. Meta-analyses were not possible due to between-study differences in the way delays were reported. Twenty-one studies were included in the review. Study-specific average times between symptom recognition and presentation to a health care provider ranged from less than 1 to 4 months in North Africa and from less than 3 to greater than 6 months in sub-Saharan Africa. Study-specific average times from presentation to diagnosis were less than 1 month in North Africa but ranged from less than 3 to greater than 6 months in sub-Saharan Africa. Reported reasons for these delays included patient-mediated (e.g., socioeconomic factors) and health system-mediated factors (e.g., referral pathways). This systematic review revealed marked delays in presentation and diagnosis of breast cancer in Africa. Identification of their drivers is crucial to the development of appropriate control strategies in the continent.

1 December 2018 in Journal of Cancer Policy
Verified
Journal Article
Open access
CECarolina Espina
Carolina Espina
ISIsabelle Soerjomataram
Isabelle Soerjomataram
DFDavid Forman
David Forman
Jose M Martin-MorenoJose M Martin-Moreno
Jose M Martin-Moreno
• National Cancer Control Programmes (NCCPs) are key elements in cancer control. • NCCPs’ role in national cancer policies of EU countries has grown significantly. • Few quantitative assessments are available to evaluate success or failure of the implementation of NCCPs. • Research on methodologies to better assess the effectiveness of cancer prevention policies should be enhanced.

1 December 2018 in Journal of Global Oncology
Verified
Journal Article
Open access
CECarolina Espina
Carolina Espina
RHRolando Herrero
Rolando Herrero
RSRengaswamy Sankaranarayanan
Rengaswamy Sankaranarayanan
EKEtienne Krug
Etienne Krug
CWChristopher P. Wild
Christopher P. Wild
JSJoachim Schüz
Joachim Schüz
Overwhelmed by an abundance of often confusing, ambiguous, or apparently contradictory messages on disease prevention in today’s multiple media streams, the general public would surely value authoritative, clear, and evidence-based instructions on how to actively contribute to the reduction of their cancer risk. The European Code Against Cancer is a set of 12 recommendations for individuals on how to reduce cancer risk. The Code carries the authority and reliability of expert scientists working under the coordination of the International Agency for Research on Cancer, the cancer research agency of the WHO. The Code’s messages are aimed at individuals and have been enthusiastically promoted by European cancer associations. The experience of developing and promoting the European Code has generated interest in developing analogous recommendations for other regions of the world. Under the overall umbrella of a World Code Against Cancer using the same International Agency for Research on Cancer methodology, regional Codes could be developed, focused on regions sufficiently large and distinct to merit development of versions adapted to regional differences in risk factors and cancer patterns. Consideration of such an adapted model illustrates why a simple translation of the European Code would not be sufficient to promote cancer prevention globally.

2 October 2018 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
TIT Inamasu
T Inamasu
MPM Patel
M Patel
CEC Espina
C Espina
APA Pentz
A Pentz
MJM Joffe
M Joffe
JSJ Schüz
J Schüz
Retrospective case-series analysis of haematological malignancies in goldmining areas of South Africa

13 November 2020 in Journal of Cancer Education
Verified
Journal Article
Open access
PDF file
RMRaúl Murillo
Raúl Murillo
COCamila Ordóñez-Reyes
Camila Ordóñez-Reyes
MCMaría Caicedo-Martínez
María Caicedo-Martínez
SVSandra Paola Vargas
Sandra Paola Vargas
EAElsa Ariza
Elsa Ariza
CECarolina Espina
Carolina Espina
Mobile health (m-health) has shown positive effects on disease prevention; however, several factors might influence its effectiveness, particularly in low- and middle-income countries. Randomized trials provide data with high internal validity but no major information on population impact. We conducted a pilot population-based study to assess the feasibility of cancer prevention through m-health in a Latin American population. A sample of affiliates to a health insurance company in Colombia was randomly selected and assigned to receive a short message service (SMS) or voice messages (VMS) during 4 weeks; weekly frequencies 2 and 7. Baseline and post-intervention surveys were conducted. Overall, 797 affiliates were contacted (SMS 393, VMS 404) but only 15.3% and 24.8% enrolled, respectively. Over 80% acceptability was observed among participants for all items evaluated (usefulness, understandability, timing, and frequency); however, 2-VMS per week was the only frequency consistent with the declared number of messages received and listened. Other frequencies resulted in high reception recall but low willingness to read/listen the messages. The willingness to be part of future programs was 20.0%. The gap between declared acceptability and practice, low participation rates, and low willingness to read/listen messages indicate m-health should be part of multicomponent interventions and should not be conceived as the sole intervention.

1 October 2021 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
CEC Espina
C Espina
Adopted on 3rd February 2021, Europe's Beating Cancer Plan aims to reduce the cancer burden for patients, their families and health systems, and is a major strategic priority of the European Commission in its present mandate. The Cancer Plan commits to updating the European Code Against Cancer and includes the objective of making “at least 80% of the population aware of the Code by 2025”. In order to measure progress towards and attainment of this goal, metrics and tools at European level would be needed. Possible options include, but are not limited to, the “Eurobarometer”. Since 1973, the European institutions commission regular public opinion surveys in all EU Member States. The European Commission's Eurobarometer Surveys is a series of multi-topic, pan-European surveys covering attitudes towards policies, economy, and health, among other topics. It comprises survey series or instruments such as the Standard Eurobarometer (regular face-to-face interviews with approximately 1,000 subjects in each Member State), the Special Eurobarometer (in-depth thematic studies relevant to the activities of the European institutions) or the Flash Eurobarometer (ad-hoc thematic surveys carried out within a short timespan), among others. Some of these options may provide a suitable tool to standardize and measure awareness and perceptions on cancer risk factors in a valid and reliable way, as well as the corresponding cancer preventive measures, and the European Code against Cancer itself, in the European population overtime. However, developments arising from the Cancer Plan, such as the recently established Knowledge Centre for Cancer of the Joint Research Centre of the European Commission, may offer more a suitable, continuous process. This brief presentation will prepare the audience for an interactive discussion on the pragmatic challenges and opportunities that lie ahead for the monitoring and evaluation of the European Code against Cancer.